Hormonal
Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces substantial, dose-dependent weight loss in adults with obesity (mean 15-21% over 72 weeks) and superior glycemic control compared to placebo and other GLP-1 agonists.
Tirzepatide is a once-weekly injection that targets two gut hormones (GIP and GLP-1) to reduce appetite and improve blood sugar. In clinical trials, it led to an average weight loss of 15-21% over 72 weeks, significantly outperforming placebo and other GLP-1 drugs like Semaglutide. It is prescribed for adults with obesity (BMI ≥30, or ≥27 with comorbidities) and requires a slow dose escalation to manage gastrointestinal side effects.
During 72 weeks treatment, Tirzepatide-treated participants achieved an average weight loss from baseline of 15.0, 19.5 and 20.9% at doses of 5 mg, 10 mg and 15 mg, respectively, compared to merely 3.1% in the placebo group [54].
Why this rating
Based on multiple Phase 3 RCTs (SURPASS, SURMOUNT) with large sample sizes and clear statistical significance.
Source
Pharmacotherapy for chronic obesity management: a look into the future
Mariana Abdel-Malek et al. · Internal and Emergency Medicine · 2023
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →